The Swedish company Laccure AB has developed a breakthrough women’s health product that is effective, safe and user-friendly. Laccure’s owners are now aiming to divest the company to a buyer with appropriate resources to launch the product.
The manufacturing process for the new product Laccure® Pessary has now been scaled up and the product is ready for market introduction. Laccure has therefore initiated a search for an established company interested in acquiring Laccure and launching the product. The board of directors of Laccure has retained Evli Corporate Finance for the exit process.
“We are proud to announce that the final development stage, the up-scaling of the manufacturing process, for Laccure® Pessary, our new, antibiotic-free, non-prescription product for the treatment and prevention of bacterial vaginosis, is now completed. The product is thus ready for launch. Our objective from the start of the project has been to sell Laccure to an established company that will take the product to market,” says Dr. Jeanette Robertsson, CEO of Laccure AB.
About Bacterial Vaginosis
Bacterial vaginosis (BV) is the most common vaginal infection in women of childbearing age and it is estimated that more than 300 million women worldwide are infected each year. Today there is a lack of effective and safe products that are also user-friendly and can be dosed with low frequency. Women are often embarrassed at having BV and their quality of life is negatively affected. BV is an imbalance of naturally occurring vaginal bacterial flora, resulting in a lack of vaginal acidity, discharge with a pronounced foul odour and inhibition of normal lactobacilli growth. Many women suffer from frequent recurrences several times per year.
About Laccure® Pessary
Laccure has successfully taken its patented product from innovation all the way through successful clinical studies, in which 80% of the women were free of their BV after a single dose, to up-scaled manufacturing. The new product is based on a proprietary substance that releases lactic acid over several days to decrease the elevated vaginal pH. The development work has focused on creating a user-friendly product that is not messy, is easy to insert and highly effective. Laccure® Pessary only needs to be administered once to treat a BV infection, and once a month as prevention for women with frequent recurrences. The product is CE-marked as a Class IIa medical device and its intended use covers both treatment and prevention of BV. Laccure® Pessary is now ready for market introduction in the EU/EES countries.
About Laccure AB
Laccure AB is a Swedish company, founded in 2007 and based in Helsingborg. Laccure is a project company of the life science development company P.U.L.S. The initial development of the company’s product was carried out at Lund University, Sweden, and at the University of Gdansk, Poland. Further pharmaceutical development and GMP manufacturing for preclinical and clinical studies were performed in collaboration with a number of contract development organisations. Laccure’s owners are now aiming to divest the company to a buyer with appropriate resources for the launch of the Laccure® Pessary.